SMAD2 and breast carcinoma: However, the TFs such as KLF5 (52%), KLF1 (39%), and SMAD2::SMAD3::SMAD4 (31%) showed significant enrichment (q < 0.1) in gained peaks and FOX family of TFs (FOXA1 28%, FOXA2 28% and FOXF2 17%) in lost peaks in breast carcinomas.